Article Sidebar

PDF
Date Published: 17/03/2023
Abstract Views: 176
Views PDF: 114
DOI: https://doi.org/10.51298/vmj.v524i1A.4656
Issue
Vol. 524 No. 1A (2023)
Section
Các bài báo
How to Cite
Đỗ, H. K. ., & Nguyễn, T. N. H. . (2023). ANALYZING THE AFFECTED FACTORS OF CHEMOTHERAPY OF TRIPLET CAP REGIMEN IN METASTATIC SALIVARY GLAND CARCINOMA. Vietnam Medical Journal, 524(1A). https://doi.org/10.51298/vmj.v524i1A.4656

ANALYZING THE AFFECTED FACTORS OF CHEMOTHERAPY OF TRIPLET CAP REGIMEN IN METASTATIC SALIVARY GLAND CARCINOMA

Hùng Kiên Đỗ1,, Thị Như Hoa Nguyễn1
1 National cancer hospital

Main Article Content

Abstract

Objective: Analyzing the affected factors of response rates and survival outcome of triplet regimen CAP chemotherapy in metastatic salivary gland carcinoma at National Cancer Hospital from Jan 2015 to Aug 2022. Patients and method: Retrospective analysis of 21 patients with metastatic salivary gland carcinoma were diagnosed and treated with chemotherapy of CAP regimen at National Cancer Hospital from Jan 2015 to Aug 2022. Results: The univarite analysis of response rate with factors including ages, sex, primary tumor location, pathology, ECOG, time to relapse and number of metastatic organ. There were no factors affecting the response rate of chemotherapy, and no significant difference with p>0.05. The univariate analysis of survival outcome showed that clinical and subclinical factors including ages, sex, primary tumor location, pathology, ECOG, and number of metastatic organ did not influence survival outcome. Conclusion: The CAP chemotherapy is one of choise for the treatment of metastatic salivary gland cancer patients, there were no clinical, subclinical factors influencing response rate and survival outcome.

Article Details

Keywords

Metastatic salivary gland cancer, CAP regimen, response rate, survival outcome

References

1. Dreyfuss AI, Clark JR, Fallon BG (1987). Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987; 60(12): 2869.
2. Kaplan MJ, Johns ME, Cantrell RW (1986). Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg. 1986;95(2):165.
3. Licitra L, Cavina R, Grandi C (1996). Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996;7(6):640.
4. Tsukuda M, Kokatsu T, Ito K, Mochimatsu I (1993). Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck. J Cancer Res Clin Oncol. 1993;119(12):756.
5. Dimery IW, Legha SS, Shirinian M (1990). Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol. 1990;8(6):1056.
6. Venook AP, Tseng A Jr, Meyers FJ (1987). Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 1987;5(6):951.
7. Airoldi M, Pedani F, Brando V (1989). Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori. 1989; 75(3):252.